Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker AIJTY
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| May 14, 2026 | SCHEDULE 13D/A (amended) | AIJTY Jianpu Technology Inc. | JYLu Holdings Ltd. | 45.87M | 11.5% | SCHEDULE 13D/A ↗ |
| May 14, 2026 | SCHEDULE 13D/A (amended) | AIJTY Jianpu Technology Inc. | Jiayan Lu | 45.87M | 11.5% | SCHEDULE 13D/A ↗ |
| Feb 12, 2026 | SCHEDULE 13G/A (amended) | AIJTY Jianpu Technology Inc. | Morgan Stanley Capital Services LLC | 22.22M | 6.0% | SCHEDULE 13G/A ↗ |
| Feb 12, 2026 | SCHEDULE 13G/A (amended) | AIJTY Jianpu Technology Inc. | Morgan Stanley | 22.22M | 6.0% | SCHEDULE 13G/A ↗ |
| Dec 3, 2025 | SCHEDULE 13D/A (amended) | AIJTY Jianpu Technology Inc. | JYLu Holdings Ltd. | 41.72M | 10.9% | SCHEDULE 13D/A ↗ |
| Dec 3, 2025 | SCHEDULE 13D/A (amended) | AIJTY Jianpu Technology Inc. | Jiayan Lu | 41.72M | 10.9% | SCHEDULE 13D/A ↗ |
| Oct 15, 2025 | SCHEDULE 13G | AIJTY Jianpu Technology Inc. | Feng Yu | 26.54M | 7.1% | SCHEDULE 13G ↗ |
| Oct 15, 2025 | SCHEDULE 13G | AIJTY Jianpu Technology Inc. | Yunfeng Investment GP II, Ltd. | 26.54M | 7.1% | SCHEDULE 13G ↗ |
| Oct 15, 2025 | SCHEDULE 13G | AIJTY Jianpu Technology Inc. | Yunfeng Investment II, L.P. | 26.54M | 7.1% | SCHEDULE 13G ↗ |
| Oct 15, 2025 | SCHEDULE 13G | AIJTY Jianpu Technology Inc. | Yunfeng Fund II, L.P. | 26.54M | 7.1% | SCHEDULE 13G ↗ |
| Oct 15, 2025 | SCHEDULE 13G | AIJTY Jianpu Technology Inc. | Article Light Limited | 26.54M | 7.1% | SCHEDULE 13G ↗ |
| Feb 18, 2025 | SCHEDULE 13D/A (amended) | AIJTY Jianpu Technology Inc. | Lucky Fish Information Technology Limited | 11.75M | 3.1% | SCHEDULE 13D/A ↗ |
| Feb 18, 2025 | SCHEDULE 13D/A (amended) | AIJTY Jianpu Technology Inc. | Sun Flower Information Technology Ltd. | 29.23M | 7.8% | SCHEDULE 13D/A ↗ |
| Feb 18, 2025 | SCHEDULE 13D/A (amended) | AIJTY Jianpu Technology Inc. | Chenchao Zhuang | 40.98M | 10.9% | SCHEDULE 13D/A ↗ |
| Feb 18, 2025 | SCHEDULE 13D/A (amended) | AIJTY Jianpu Technology Inc. | JYLu Holdings Ltd. | 37.16M | 9.8% | SCHEDULE 13D/A ↗ |
| Feb 18, 2025 | SCHEDULE 13D/A (amended) | AIJTY Jianpu Technology Inc. | Jiayan Lu | 37.16M | 9.8% | SCHEDULE 13D/A ↗ |
| Feb 18, 2025 | SCHEDULE 13D/A (amended) | AIJTY Jianpu Technology Inc. | Mount Bonnell Limited | 15.59M | 4.2% | SCHEDULE 13D/A ↗ |
| Feb 18, 2025 | SCHEDULE 13D/A (amended) | AIJTY Jianpu Technology Inc. | LEFT BK Holdings Ltd. | 22.17M | 5.8% | SCHEDULE 13D/A ↗ |
| Feb 18, 2025 | SCHEDULE 13D/A (amended) | AIJTY Jianpu Technology Inc. | Daqing Ye | 37.76M | 10.0% | SCHEDULE 13D/A ↗ |
| Feb 18, 2025 | SCHEDULE 13D/A (amended) | AIJTY Jianpu Technology Inc. | Neil Nanpeng Shen ("NS") | 62.34M | 16.6% | SCHEDULE 13D/A ↗ |
| Feb 18, 2025 | SCHEDULE 13D/A (amended) | AIJTY Jianpu Technology Inc. | SNP China Enterprises Limited ("SNP China Enterprises") | 62.34M | 16.6% | SCHEDULE 13D/A ↗ |
| Feb 18, 2025 | SCHEDULE 13D/A (amended) | AIJTY Jianpu Technology Inc. | HSG Holding Ltd ("HSG Holding") | 62.34M | 16.6% | SCHEDULE 13D/A ↗ |
| Feb 18, 2025 | SCHEDULE 13D/A (amended) | AIJTY Jianpu Technology Inc. | HSG Growth III Management, L.P. ("HSG Growth III Management") | 6.38M | 1.7% | SCHEDULE 13D/A ↗ |
| Feb 18, 2025 | SCHEDULE 13D/A (amended) | AIJTY Jianpu Technology Inc. | HongShan Capital Growth Fund III, L.P. ("HongShan Capital Growth Fund III") | 6.38M | 1.7% | SCHEDULE 13D/A ↗ |
| Feb 18, 2025 | SCHEDULE 13D/A (amended) | AIJTY Jianpu Technology Inc. | HSG GF Holdco III-A, Ltd. ("HSG GF Holdco III-A") | 6.38M | 1.7% | SCHEDULE 13D/A ↗ |
| Feb 18, 2025 | SCHEDULE 13D/A (amended) | AIJTY Jianpu Technology Inc. | HSG Venture IV Management, L.P. ("HSG Venture IV Management") | 55.95M | 14.9% | SCHEDULE 13D/A ↗ |
| Feb 18, 2025 | SCHEDULE 13D/A (amended) | AIJTY Jianpu Technology Inc. | HongShan Capital Venture Fund IV, L.P. ("HongShan Capital Venture Fund IV") | 55.95M | 14.9% | SCHEDULE 13D/A ↗ |
| Feb 18, 2025 | SCHEDULE 13D/A (amended) | AIJTY Jianpu Technology Inc. | HSG CV IV Senior Holdco, Ltd. ("HSG CV IV Senior Holdco") | 55.95M | 14.9% | SCHEDULE 13D/A ↗ |
| Feb 18, 2025 | SCHEDULE 13D/A (amended) | AIJTY Jianpu Technology Inc. | HSG CV IV Holdco, Ltd. ("HSG CV IV Holdco") | 55.95M | 14.9% | SCHEDULE 13D/A ↗ |
29 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:54 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances